Flow Cytometry Market - Growth, Trends, and Forecasts (2023 - 2028)

Flow Cytometry Market - Growth, Trends, and Forecasts (2023 - 2028)

At the moment, the flow cytometry market is worth USD 4,874.12 million, and it is expected to reach USD 8,071.86 million by the end of the forecast period, with a CAGR of 8.64%.

The COVID-19 pandemic impacted the growth of the flow cytometry market. For instance, an article published in the journal Frontiers in Immunology in January 2022 reported that a flow cytometry-based high-throughput screening system is proposed for testing COVID-19 cases where the virus particle binds to specific primary antibodies and the resultant virus–antibody complex then binds to fluorescently tagged secondary antibodies. The fluorescence signal could be measured in a flow channel for the qualitative detection of the virus in the test sample. Thus, flow cytometry was used in the diagnosis of COVID-19 samples, and its use significantly increased during the pandemic. In the current scenario, with the decrease in COVID-19 cases, the demand for flow cytometry may stabilize compared to the beginning of the pandemic. However, according to research in the pharmaceutical and healthcare industries, the demand for flow cytometry is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are the growing adoption of flow cytometry in stem cell research and the increasing applications of flow cytometry in clinical research. In April 2022, for example, the International Journal of Laboratory Haematology published an article saying that flow cytometry is a method used in many different situations to look at the characteristics of a mixed cell population from peripheral blood (PB), bone marrow (BM), and solid tissues that can be broken up into single cells for further study.Thus, such use of flow cytometry is driving the growth of the studied market.

Additionally, FlowMetric Company reported in a May 2022 article that flow cytometry techniques have been a useful tool for drug development with the advantage of enabling multiplexed phenotypic primary screening of cells and screening of sources for biological drugs like antibodies.The article also said that flow cytometry is very important in almost every step of developing CAR-T therapy.This includes figuring out what's wrong with the patient, figuring out what the product is made of and how pure it is, and figuring out what's going on after the infusion (like the patient's functional state and the loss of the target antigen).Flow cytometry is used a lot in the process of making new drugs. This helps the studied market grow.

Also, the high number of cases of Leishmania is increasing the demand for flow cytometry. For example, an article published in the journal Biochemistry Research International in April 2022 stated that visceral leishmaniasis (VL), also known as kala-azar, affects approximately 50,000–90,000 people worldwide each year. Thus, such a high number of VL cases is fueling the growth of the studied market.

Furthermore, new product launches by key market players are propelling the studied market's growth. For instance, in August 2021, Becton, Dickinson, and Company launched a new benchtop cell analyzer, the BD FACSymphony A1 Cell Analyzer. The fluorescence-activated cell analyzer is expected to equip laboratories of all sizes with sophisticated flow cytometry capabilities.

So, the studied market is expected to grow a lot over the next few years because stem cell research is using flow cytometry more and more, flow cytometry is being used more and more in clinical research, there are a lot of leishmaniasis cases, and new products are coming out. However, due to the lack of awareness about the potential benefits of flow cytometry techniques and the high cost of the equipment, the growth of the studied market may be hindered during the forecast period.

Stem cell therapy is expected to make up a big part of the market in terms of how it is used. Flow cytometry is used to find, describe, and separate stem cells for research and other purposes. This is because it can quickly take quantitative measurements on a single cell in a group of different cells.

Flow cytometry is used a lot to diagnose and find early signs of many diseases, which is a big reason why this segment has such a big share of the market. The growth of the stem cell research market, the use of recombinant DNA technology to make antibodies, and the improvement of tandem flow cytometry technologies are all things that are expected to help the major players in the flow cytometry market grow. For instance, according to the National Clinical Trial Registry (NCT), as of April 21, 2021, there were about 320 registered clinical trials across different phases of development related to stem cell therapy in Germany. So, the demand for flow cytometry is likely to grow in the coming years as research into stem cell therapy grows.

Also, in April 2022, The Official Journal of the International Clinical Cytometry Society published an article saying that flow cytometry's ability to quickly process large numbers of cells and use multiple parameters to identify them makes it possible to get enough of even the rarest stem cells for accurate end-point analysis or use later on. Flow cytometry and/or cell sorting experiments that are done right also capture highly pure and live cell populations. Thus, the wide application of flow cytometry is driving the growth of this segment.

As a result, the increasing use of flow cytometry in stem cell research and the number of stem cell clinical trials are what are driving this segment's growth.

North America consists of three countries: the United States, Canada, and Mexico. The region is expected to witness significant growth over the forecast period owing to rising research, rising leishmania and HIV cases, and the presence of key market players in the region.

Mexico is seeing a rise in the number of people with leishmaniasis, and the role of flow cytometry in figuring out a patient's prognosis has become more important since the invention of tests to find disease and measure drug resistance.For example, a December 2022 article in the journal Tropical Medicine and Infectious Disease talked about how the number of cases of leishmania has been rising over the past five years.Because there are more and more people with leishmaniasis, demand for flow cytometry to figure out prognosis is likely to rise in the coming years.

The growth of the studied market is also being helped by the fact that Canada has a lot of HIV cases.For instance, in July 2022, the Government of Canada reported that an estimated 62,790 people were living with HIV in Canada during 2020–2021. Thus, a high number of HIV cases may increase the demand for frequent disease diagnosis, which may increase the demand for flow cytometry in the country, thereby driving the growth of the studied market.

The market is also growing because there are more and more research and development projects going on.In a 2021 update from the University of North Dakota, the UND Center of Biomedical Research Excellence (CoBRE) in host-pathogen interactions (HPI) said that funding from the National Institutes of Health (NIH) will continue through Phase 2 of the project.The USD 10.7 million renewal is given so that researchers can learn more about how the body reacts to viral, bacterial, and parasitic infections that cause both short-term and long-term inflammatory disorders.The Center will also help the School of Medicine and Health Sciences (SMHS) and UND do more innovative research by supporting three Phase 1 core facilities, such as flow cytometry.Such developments are anticipated to contribute to the growth of the market in the United States.

Also, the growth of the studied market in the region is helped by the release of new products.For example, Thermo Fisher Scientific released the Invitrogen Attune CytPix Flow Cytometer in June 2021. It is an imaging-enhanced flow cytometer that uses a high-speed camera and acoustic focusing flow cytometry technology.The Attune CytPix lets users collect high-performance fluorescent flow cytometry data from cells while also taking high-resolution brightfield images. This lets them match images with their flow cytometry data to better understand the shape and quality of the cells.

Thus, due to the rising leishmania and HIV cases, rising research and development, and new product launches, the market is expected to witness significant growth in the region over the forecast period.

The Flow Cytometry Market is considered competitive due to the presence of many players. These players hold a huge share of the market and are likely to remain in a similar competitive environment for the next few years. Key players in the market include Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter Inc.), Sysmex Corporation, Bio-Rad Laboratories Inc., and Luminex Corporation.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support